US-based Hyperion Biosystems and Colorcon on Tuesday declared a licensing agreement to commercialise and market a jointly-developed, anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products.
Colorcon is a supplier of film coating systems, modified release technology, specialty excipients and functional packaging for the healthcare industry. Hyperion Biosystems applies its expertise in optical detection, artificial intelligence (AI) and physics-based algorithms to create solutions for authentication, chemical sensing, product aging, tamper evidence and diagnostics for multiple industries.
On-dose authentication is claimed to integrates security measures directly into the dosage form, providing fast product verification and traceability. When products are separated from their original packaging, taggants applied directly within the film coating provides a convenient way for companies to verify whether a product is authentic in markets around the world.
"This agreement is the result of a multi-year relationship between Hyperion Biosystems and Colorcon," said Jason Cox, PhD, Hyperion Biosystems CEO. "Our teams have closely collaborated to create a unique solution for on-dose authentication. By combining our expertise in authentication additives and our core Halo product suite, we are supporting Colorcon's efforts to solve the highly complex and growing challenge of counterfeit pharmaceutical and nutraceutical products in the global market."
"Colorcon is evaluating various ways to add on-dose authentication technology to its SoteriaRx product portfolio to meet the FDA requirements around physical-chemical identifiers (PCID)," said Gary Pond, Colorcon director of Strategic Business Development. "This agreement with Hyperion Biosystems demonstrates our ongoing commitment to customers by offering innovative solutions that will improve security in the pharmaceutical supply chain, seamlessly integrating into existing manufacturing processes and most importantly, safeguarding both patients and trusted brands."
Endo adds new concentration to ADRENALIN ready-to-use premixed bag line
OS Therapies launches OS Animal Health to target USD150m canine osteosarcoma market
Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties
FDA extends Biohaven's PDUFA date for troriluzole NDA for spinocerebellar ataxia
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software
Benuvia Operations enters Dronabinol API commercial supply agreement with US pharmaceutical company
Hyperion Biosystems and Colorcon sign licensing agreement
Gensco Pharma acquires RizaFilm and RizaPort global rights and IP